TORONTO, ON / ACCESSWIRE / September 12, 2019 / Aquarius Surgical Technologies Inc. (ASTI:CSE) (“ASTI” or “the Company”) is pleased to announce that Camp Lejuene, a naval hospital in North Carolina, has committed to the purchase of ASTI’s HYPHO laser device, following a successful comprehensive clinical evaluation made by ASTI’s newly signed distributor, Med Resources Inc.
Gordon Willox, Founder and President of ASTI, commented: “This is a remarkable achievement for us as it opens a great opportunity for ASTI’s products to be adopted at over 200 military and naval hospitals in the US. We are very pleased with the rapid progress that we’ve made since signing a distribution agreement with Med Resources.”
ASTI’s equipment sales were $134,000 in the last fiscal year and have increased to $226,000 in the first quarter of the current fiscal year and $178,000 for the first two months of the second quarter of the current fiscal year. Fiber sales have increased from $21,000 per month in the last fiscal year and the first quarter of the current year to $45,000 per month in the first two months of the second quarter of the current fiscal year. This trend is expected to continue with further investment in marketing initiatives.
ASTI is currently raising up to $2.5M via a private placement offering, the net proceeds of which would go towards adding more sales teams to further grow the Company’s market presence.
About Aquarius Surgical Technologies Inc.
Aquarius Surgical Technologies (ASTI: CSE) is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs. Learn more by visiting the Investors tab on ASTI’s website https://surgicallasersinc.com/.
For more information, please contact:
Gordon Willox, President
Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Neither the CSE Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Aquarius Surgical Technologies Inc. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Aquarius Surgical Technologies Inc.
SOURCE: Aquarius Surgical Technologies Inc.
View source version on accesswire.com: